PhilipGreysonBlackMD
Pediatric Pulmonology • Kansas City, MOAssociate Professor, Pediatrics, University of Missouri, Kansas City School of Medicine
Dr. Black is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2401 Gillham Rd
Kansas City, MO 64108Phone+1 816-234-3000
Education & Training
University of Utah HealthResidency, Pediatrics, 1983 - 1984
Tulane UniversityResidency, Pediatrics, 1982 - 1983- University of Utah HealthResidency, Pediatrics, 1981 - 1982
University of Kansas School of MedicineInternship, Transitional Year, 1979 - 1980- University of Kansas School of MedicineClass of 1979
Certifications & Licensure
UT State Medical License 1900 - Present
MO State Medical License 1990 - 2025
KS State Medical License 1990 - 2022
TX State Medical License 1988 - 1990
LA State Medical License 1982 - 1983- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
- OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
- Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) Start of enrollment: 2016 Oct 21
Publications & Presentations
PubMed
- 210 citationsEfficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3...Felix Ratjen, Christopher Hug, Gautham Marigowda, S. Tian, Xiaohong Huang
The Lancet. Respiratory Medicine. 2017-07-01 - 30 citationsChanges in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.Felix Ratjen, Michelle Klingel, Philip Black, Michael R. Powers, Hartmut Grasemann
American Journal of Respiratory and Critical Care Medicine. 2018-08-15 - 176 citationsIvacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
